These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30910803)

  • 1. MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma.
    Kim E; Zucconi BE; Wu M; Nocco SE; Meyers DJ; McGee JS; Venkatesh S; Cohen DL; Gonzalez EC; Ryu B; Cole PA; Alani RM
    Cancer Res; 2019 May; 79(10):2649-2661. PubMed ID: 30910803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.
    Wang R; He Y; Robinson V; Yang Z; Hessler P; Lasko LM; Lu X; Bhathena A; Lai A; Uziel T; Lam LT
    Mol Cancer Ther; 2018 Dec; 17(12):2543-2550. PubMed ID: 30266801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators.
    Vachtenheim J; Sestáková B; Tuhácková Z
    Pigment Cell Res; 2007 Feb; 20(1):41-51. PubMed ID: 17250547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
    Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
    J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.
    Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B
    Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition.
    Guo W; Ma J; Yang Y; Guo S; Zhang W; Zhao T; Yi X; Wang H; Wang S; Liu Y; Dai W; Chen X; Shi Q; Wang G; Gao T; Li C
    Clin Cancer Res; 2020 Jun; 26(11):2725-2739. PubMed ID: 32034077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of CBP/p300 recruitment by the microphthalmia-associated transcription factor.
    Brown AD; Vergunst KL; Branch M; Blair CM; Dupré DJ; Baillie GS; Langelaan DN
    Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119520. PubMed ID: 37353163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression.
    Ogiwara H; Sasaki M; Mitachi T; Oike T; Higuchi S; Tominaga Y; Kohno T
    Cancer Discov; 2016 Apr; 6(4):430-45. PubMed ID: 26603525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease.
    Travnickova J; Wojciechowska S; Khamseh A; Gautier P; Brown DV; Lefevre T; Brombin A; Ewing A; Capper A; Spitzer M; Dilshat R; Semple CA; Mathers ME; Lister JA; Steingrimsson E; Voet T; Ponting CP; Patton EE
    Cancer Res; 2019 Nov; 79(22):5769-5784. PubMed ID: 31582381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation reprograms MITF target selectivity and residence time.
    Louphrasitthiphol P; Loffreda A; Pogenberg V; Picaud S; Schepsky A; Friedrichsen H; Zeng Z; Lashgari A; Thomas B; Patton EE; Wilmanns M; Filippakopoulos P; Lambert JP; Steingrímsson E; Mazza D; Goding CR
    Nat Commun; 2023 Sep; 14(1):6051. PubMed ID: 37770430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.
    Giotopoulos G; Chan WI; Horton SJ; Ruau D; Gallipoli P; Fowler A; Crawley C; Papaemmanuil E; Campbell PJ; Göttgens B; Van Deursen JM; Cole PA; Huntly BJ
    Oncogene; 2016 Jan; 35(3):279-89. PubMed ID: 25893291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
    Haery L; Lugo-Picó JG; Henry RA; Andrews AJ; Gilmore TD
    Mol Cancer; 2014 Feb; 13():29. PubMed ID: 24529102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells.
    Vachtenheim J; Ondrusová L; Borovanský J
    Biochem Biophys Res Commun; 2010 Feb; 392(3):454-9. PubMed ID: 20083088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor.
    Coe EA; Tan JY; Shapiro M; Louphrasitthiphol P; Bassett AR; Marques AC; Goding CR; Vance KW
    PLoS Genet; 2019 Dec; 15(12):e1008501. PubMed ID: 31881017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone acetyltransferase p300 mediates histone acetylation of PS1 and BACE1 in a cellular model of Alzheimer's disease.
    Lu X; Deng Y; Yu D; Cao H; Wang L; Liu L; Yu C; Zhang Y; Guo X; Yu G
    PLoS One; 2014; 9(7):e103067. PubMed ID: 25051175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes.
    Bandyopadhyay D; Okan NA; Bales E; Nascimento L; Cole PA; Medrano EE
    Cancer Res; 2002 Nov; 62(21):6231-9. PubMed ID: 12414652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The C-terminal transactivation domain of MITF interacts promiscuously with co-activator CBP/p300.
    Brown AD; Lynch K; Langelaan DN
    Sci Rep; 2023 Sep; 13(1):16094. PubMed ID: 37752231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape.
    Zamperla MG; Illi B; Barbi V; Cencioni C; Santoni D; Gagliardi S; Garofalo M; Zingale GA; Pandino I; Sbardella D; Cipolla L; Sabbioneda S; Farsetti A; Ripamonti C; Fossati G; Steinkühler C; Gaetano C; Atlante S
    Clin Epigenetics; 2024 Aug; 16(1):109. PubMed ID: 39155390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor.
    Choi KC; Park S; Lim BJ; Seong AR; Lee YH; Shiota M; Yokomizo A; Naito S; Na Y; Yoon HG
    Biochem J; 2011 Jan; 433(1):235-44. PubMed ID: 20955177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.